|
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. |
|
|
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst) |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Serono (Inst) |
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst); Takeda (Inst) |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst) |
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunophotonics (Inst); InnoMedica (Inst); Intensity Therapeutics (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Janssen-Cilag; Pfizer; Roche; Takeda |
Travel, Accommodations, Expenses - AstraZeneca; Takeda |
|
|
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Illumina (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst) |
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines; Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo; Debiopharm Group (Inst); Illumina (Inst); Incyte; Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst) |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi |
(OPTIONAL) Uncompensated Relationships - ESMO; European Thoracic Oncology Platform (ETOP); Journal of Thoracic Oncology |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda |
Travel, Accommodations, Expenses - Pfizer (Inst); Roche (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen; MSD Oncology; Novartis; Pfizer; Roche; Takeda |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |